Accuray Stock Price, News & Analysis (NASDAQ:ARAY)

Accuray trades on the NASDAQ under the ticker symbol "ARAY."

Accuray Incorporated (NASDAQ:ARAY) issued its quarterly earnings data on Thursday, August, 15th. The medical equipment provider reported ($0.02) earnings per share for the quarter, missing the Zacks' consensus estimate of $0.03 by $0.05. The medical equipment provider had revenue of $117.42 million for the quarter, compared to analysts' expectations of $116.09 million. Accuray had a negative return on equity of 26.69% and a negative net margin of 3.92%. During the same period last year, the business earned ($0.01) earnings per share. View Accuray's Earnings History.

Accuray is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for Accuray.

Accuray issued an update on its FY 2020 earnings guidance on Thursday, August, 15th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $410-420 million, compared to the consensus revenue estimate of $436.86 million.

3 equities research analysts have issued 1-year price targets for Accuray's shares. Their predictions range from $3.90 to $4.00. On average, they anticipate Accuray's stock price to reach $3.95 in the next year. This suggests a possible upside of 33.0% from the stock's current price. View Analyst Price Targets for Accuray.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accuray in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Accuray.

News articles about ARAY stock have trended somewhat negative on Sunday, InfoTrie reports. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Accuray earned a daily sentiment score of -1.3 on InfoTrie's scale. They also assigned media headlines about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Accuray.

Some companies that are related to Accuray include AtriCure (ATRC), Luminex (LMNX), Orthofix Medical (OFIX), Tactile Systems Technology (TCMD), Shockwave Medical (SWAV), Axonics Modulation Technologies (AXNX), Cerus (CERS), Anika Therapeutics (ANIK), LeMaitre Vascular (LMAT), AngioDynamics (ANGO), SurModics (SRDX), MiMedx Group (MDXG), Antares Pharma (ATRS), Orthopediatrics (KIDS) and Intersect ENT (XENT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Accuray investors own include NVIDIA (NVDA), Activision Blizzard (ATVI), Intel (INTC), Advanced Micro Devices (AMD), Tesla (TSLA), Exelixis (EXEL), Intuitive Surgical (ISRG), AVEO Pharmaceuticals (AVEO), Cypress Semiconductor (CY) and Depomed (DEPO).

Accuray's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.33%), Renaissance Technologies LLC (5.79%), Primecap Management Co. CA (5.34%), Vanguard Group Inc. (4.80%), Heartland Advisors Inc. (3.94%) and D. E. Shaw & Co. Inc. (3.13%). Company insiders that own Accuray stock include Alaleh Nouri, Andrew J Kirkpatrick, Jesse Chew, Joseph E Whitters, Joshua Levine, Kelly Londy, Kevin Waters, Patrick Spine and Shigeyuki Hamamatsu. View Institutional Ownership Trends for Accuray.

ARAY stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., JPMorgan Chase & Co., BlackRock Inc., Renaissance Technologies LLC, Marshall Wace LLP, AQR Capital Management LLC, Algert Global LLC and Wells Fargo & Company MN. Company insiders that have sold Accuray company stock in the last year include Andrew J Kirkpatrick, Jesse Chew, Joshua Levine, Patrick Spine and Shigeyuki Hamamatsu. View Insider Buying and Selling for Accuray.

ARAY stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Nuveen Asset Management LLC, D. E. Shaw & Co. Inc., Boston Partners, Wedge Capital Management L L P NC, Crestline Management LP, SG Americas Securities LLC and Paloma Partners Management Co. Company insiders that have bought Accuray stock in the last two years include Joseph E Whitters and Joshua Levine. View Insider Buying and Selling for Accuray.

Shares of ARAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ARAY stock can currently be purchased for approximately $2.97.

Accuray has a market capitalization of $263.68 million and generates $418.79 million in revenue each year. The medical equipment provider earns $-16,430,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis. Accuray employs 998 workers across the globe.View Additional Information About Accuray.

The official website for Accuray is http://www.accuray.com/.

Accuray's mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The medical equipment provider can be reached via phone at 408-716-4600 or via email at [email protected]